Latest News
Hopkins researchers recommend reclassifying psilocybin, the drug in 'amgic mushrooms , from schedule I to schedule IV.
February 20,2018
Researchers at John Hopkins suggest that if psilocybin clears Phase III clinical trials, it should be re-categorized from a schedule I drug—one with no known medical potential—to a schedule IV drug such as prescription sleep aids, but with tighter control.
Taking Psychedelics Seriously
January 3, 2011
Psychiatric research in the 1950s and 1960s showed potential for psychedelic medications to markedly alleviate depression and suffering associated with terminal illness. More recent published studies have demonstrated the safety and efficacy of psilocybin, MDMA, and ketamine when administered in a medically supervised and monitored approach. A single or brief series of sessions often results in substantial and sustained improvement among people with treatment-resistant depression and anxiety, including those with serious medical conditions.
Experiences of ‘Ultimate Reality’ or ‘God’ Confer Lasting Benefits to Mental Health
April 23, 2019
People over the millennia have reported having deeply moving religious experiences either spontaneously or while under the influence of psychedelic substances such as psilocybin-containing mushrooms or the Amazonian brew ayahuasca, and a portion of those experiences have been encounters with what the person regards as “God” or “ultimate reality.”
Researchers think magic mushrooms could have the potential to treat depression
February 13, 2019
Magic mushrooms have been on the psychedelic scene for decades, but they're currently gaining traction in the medical community as a potential treatment for depression. In November 2018, researchers at Johns Hopkins published a paper urging the government to make psilocybin, the main psychoactive element in magic mushrooms, legally available in clinical settings,
.png)
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act
November 2018
This review assesses the abuse potential of medically-administered psilocybin, following the structure of the 8 factors of the US Controlled Substances Act (CSA). Research suggests the potential safety and efficacy of psilocybin in treating cancer-related psychiatric distress and substance use disorders, setting the occasion for this review. A more extensive assessment of abuse potential according to an 8-factor analysis would eventually be required to guide appropriate schedule placement
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
January 3, 2011
In recent years, there has been a growing awareness that there is a psychological, spiritual, and existential crises often encountered by patients with cancer and their families need to be addressed more vigorously. Those studies exploring the use of hallucinogens treating anxiety, despair, and isolation described critically ill individuals undergoing psychospiritual epiphanies, often with powerful and sustained improvement in mood and anxiety as well as diminished need for narcotic pain medication.
